AR060448A1 - Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo - Google Patents

Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo

Info

Publication number
AR060448A1
AR060448A1 ARP070101581A ARP070101581A AR060448A1 AR 060448 A1 AR060448 A1 AR 060448A1 AR P070101581 A ARP070101581 A AR P070101581A AR P070101581 A ARP070101581 A AR P070101581A AR 060448 A1 AR060448 A1 AR 060448A1
Authority
AR
Argentina
Prior art keywords
seq
nucleotides
syk
region
mrna
Prior art date
Application number
ARP070101581A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR060448A1 publication Critical patent/AR060448A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Abstract

Se proporciona interferencia de ARN para la inhibicion de la expresion de ARNm de tirosina quinasa de bazo (Syk, segun sus siglas en inglés), en particular, para tratar pacientes que tienen una afeccion inflamatoria relacionada con Syk o que se encuentran en riesgo de desarrollar una afeccion inflamatoria relacionada con Syk tal como conjuntivitis alérgica, inflamacion acular, dermatitis, rinitis, asma, alergia o enfermedad de células cebadas. Reivindicacion 1: El uso de ARN de interferencia para la manufactura de un medicamento para atenuar la expresion de ARNm de Syk de un sujeto, que comprende: administrar al sujeto una composicion que comprende una cantidad eficaz de ARN de interferencia (iRNA) que tiene una longitud de 19 a 49 nucleotidos y un portador aceptable para uso farmacéutico, comprendiendo el ARN de interferencia una region seleccionada del grupo formado por: una region de por lo menos 13 nucleotidos contiguos que tiene por lo menos 90% de complementariedad entre secuencias con, o por lo menos 90% de identidad de secuencias con, los 13 nucleotidos penultimos del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; una region de por lo menos 14 nucleotidos contiguos que tiene por lo menos 85% de complementariedad entre secuencias a, o por lo menos 85% de identidad de secuencias con, los penultimos 14 nucleotidos del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; y una region de por lo menos 15, 16, 17 o 18 nucleotidos contiguos que tiene por lo menos 80% de complementariedad entre secuencias a, o por lo menos 80% de identidad de secuencias con, los penultimos 15, 16, 17 o 18 nucleotidos, respectivamente, del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; donde la expresion de ARNm de Syk es atenuada de ese modo.
ARP070101581A 2006-04-13 2007-04-13 Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo AR060448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
AR060448A1 true AR060448A1 (es) 2008-06-18

Family

ID=38610402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101581A AR060448A1 (es) 2006-04-13 2007-04-13 Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo

Country Status (13)

Country Link
US (4) US8048863B2 (es)
EP (3) EP2662446A3 (es)
JP (1) JP2009533475A (es)
KR (1) KR20080110900A (es)
CN (2) CN101443020A (es)
AR (1) AR060448A1 (es)
AU (2) AU2007238027B2 (es)
BR (1) BRPI0709506A2 (es)
CA (1) CA2649138C (es)
MX (2) MX345954B (es)
TW (2) TW200808360A (es)
WO (1) WO2007121347A2 (es)
ZA (1) ZA200808744B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815536A (zh) * 2007-10-01 2010-08-25 爱尔康研究有限公司 自补aav介导的干扰rna分子递送以治疗或预防眼病
WO2009144230A1 (en) * 2008-05-26 2009-12-03 Universität Zürich Protamine/rna nanoparticles for immunostimulation
AU2009330458B2 (en) * 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
EP3241903A4 (en) * 2014-12-29 2018-07-04 Bonac Corporation Composition containing nucleic acid molecule stably
US10888391B2 (en) 2015-05-29 2021-01-12 Ablacon Inc Optical force sensing assembly for an elongated medical device
EP3369816B1 (en) 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
JPH11507824A (ja) * 1995-06-07 1999-07-13 ユニバーシティー・オブ・ペンシルバニア 食作用を阻害する方法
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
EP2157191B1 (en) * 2002-10-01 2013-12-25 Epigenomics AG Use of PITX2 nucleic acids for the improved treatment of breast cell proliferative disorders
EP2278005A3 (en) * 2002-11-14 2012-05-23 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060275762A1 (en) * 2002-11-22 2006-12-07 Bio- Think Tank Co., Ltd., Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
WO2005049838A2 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
EP1904649A2 (en) * 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
ES2562428T3 (es) * 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
UY31267A1 (es) 2007-08-03 2009-01-05 Alcon Res Ltd Inhibición del pasaje de senalización del tnfa relacionada con arni para el tratamiento de la angiogénesis ocular

Also Published As

Publication number Publication date
CN101443020A (zh) 2009-05-27
US20090324507A1 (en) 2009-12-31
EP3156486A2 (en) 2017-04-19
EP2004240A4 (en) 2010-12-15
EP2662446A2 (en) 2013-11-13
EP3156486A3 (en) 2017-07-12
TW201336514A (zh) 2013-09-16
CN101972483A (zh) 2011-02-16
US20110288157A1 (en) 2011-11-24
ZA200808744B (en) 2009-12-30
EP2004240A2 (en) 2008-12-24
US8865671B2 (en) 2014-10-21
MX345954B (es) 2017-02-16
BRPI0709506A2 (pt) 2011-07-19
AU2007238027B2 (en) 2013-08-15
WO2007121347A3 (en) 2008-12-04
US9371529B2 (en) 2016-06-21
WO2007121347A2 (en) 2007-10-25
JP2009533475A (ja) 2009-09-17
EP2662446A3 (en) 2014-04-02
US8048863B2 (en) 2011-11-01
US20160257963A1 (en) 2016-09-08
TW200808360A (en) 2008-02-16
CA2649138C (en) 2018-04-03
AU2007238027A1 (en) 2007-10-25
US20140357695A1 (en) 2014-12-04
AU2013207601B2 (en) 2016-11-17
CA2649138A1 (en) 2007-10-25
KR20080110900A (ko) 2008-12-19
MX2008013068A (es) 2008-12-16

Similar Documents

Publication Publication Date Title
AR060448A1 (es) Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo
PE20190443A1 (es) Moleculas de acido nucleico para la reduccion de arnm de papd5 o papd7 para tratar la infeccion por hepatitis b
UY32085A (es) Inhibidores de cinasa y métodos para su uso
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
AR061064A1 (es) Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfa
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
NI200900106A (es) Inhibidores de la actividad de la akt.
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
AR061066A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
DOP2013000054A (es) Imidazopiridazinas sustituidas
ECSP10010559A (es) Compuestos heterociclicos novedosos y usos de los mismos
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
BR112012014760A2 (pt) "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CR10609A (es) Moduladores de benzofuro-y benzotienopirimidina del receptor h4 de histamina
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
UY32312A (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
CL2020002563A1 (es) Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b

Legal Events

Date Code Title Description
FB Suspension of granting procedure